MDS 2021 | How can we develop better DMTs in Huntington’s disease?

Anne Rosser, PhD, FRCP, Cardiff University, Cardiff, UK, underlines the importance of better understanding the fundamental mechanisms of Huntington’s disease pathology to improve current treatment approaches and develop new effective disease modifying therapies (DMTs). It is particularly important to determine how the mutant huntingtin protein causes disease, as well as how the normal protein functions. This interview took place during the 2021 International Congress of Parkinson’s Disease and Movement Disorders.